Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...

Very high Lp(a) also correlated with higher risks of ischemic stroke and cardiovascular mortality in the Women’s Health Study ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Elevated lipoprotein(a) increases the risk of major adverse cardiovascular events in patients with and without preexisting atherosclerotic cardiovascular disease (ASCVD), a new study shows. The ...

Please provide your email address to receive an email when new articles are posted on . Lp(a) screening should be done once for all adults and high-risk children. Lp(a) level can help guide CVD risk ...